阿比特龙或恩扎卢胺治疗不影响前列腺癌患者对新冠疫苗的免疫应答
该研究纳入25例接受雄激素受体靶向药物(ARTA)治疗的前列腺癌患者,评估其接种新冠疫苗后的免疫应答与安全性。数据显示,这些患者产生的SARS-CoV-2中和抗体水平与健康志愿者相似,且未观察到安全问题。
要点
- ARTA治疗患者接种新冠疫苗后可产生与健康志愿者相似的中和抗体。
- 未观察到与疫苗接种相关的安全问题。
- 年龄、基础疾病和抗肿瘤治疗可能负向影响疫苗免疫应答,但ARTA治疗似不加重免疫抑制。
核心结论
- 接受阿比特龙或恩扎卢胺治疗的前列腺癌患者接种新冠疫苗后能产生中和抗体,且安全性良好。
研究设计与样本
- 研究报告25例接受ARTA治疗并接种新冠疫苗的前列腺癌患者的数据。
主要发现
- 这些患者产生针对SARS-CoV-2的中和抗体,与健康志愿者相似。
- 未观察到安全问题。
临床怎么用
- 接受ARTA治疗的前列腺癌患者可正常接种新冠疫苗,无需因治疗而担忧免疫应答受损。
局限性
- 样本量较小(25例),缺乏对照组的详细描述。
- 原文未报告抗体滴度、阳性率等具体数值及统计比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data regarding the safety and efficacy of COVID-10 vaccines among cancer patients are lacking. Factors such as age, underlying disease and antineoplastic treatment confer negatively to the immune response due to vaccination. The degree of immunosuppression though may be lessen by targeted treatments like the androgen receptor-targeted agents (ARTA) that are commonly used in patients with metastatic prostate cancer. Herein, we report our data on 25 patients with prostate cancer under treatment with ARTA who were vaccinated for COVID-19. Our data suggest that these patients develop neutralizing antibodies against SARS-CoV-2 similarly to healthy volunteers. No safety issues were noted.
引用
- Liontos M, Terpos E, Kunadis E, et al. Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. Prostate Cancer Prostatic Dis. 2021. PMID: 34628475. doi:10.1038/s41391-021-00455-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。